Elezanumab Granted Orphan Drug, Fast Track Designations for Spinal Cord Injury
Elezanumab is a monoclonal antibody of the human IgG1 isotype that works by binding selectively to repulsive guidance molecule A.
Musculoskeletal Disorders
Gabapentin Does Not Lower Pain Scores in Chronic Pelvic Pain
Treatment also linked to more serious adverse events.
Xeljanz Approved for Active Polyarticular Course Juvenile Idiopathic Arthritis
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
Glucocorticoids Linked to Hospitalized Infection Risk in RA
Risk for hospitalized infections up for patients with RA receiving DMARDs with continued glucocorticoid use
USPSTF Finds Evidence Lacking for Vitamin D Screening
Current evidence inadequate to determine benefits and harms of screening for vitamin D deficiency
Curcuma longa Extract Improves Knee Pain in Osteoarthritis
CL improved pain but did not change effusion-synovitis volume or cartilage composition.
Early Therapy for Rheumatoid Arthritis May Slow Heart Disease
RA treatment response does not appear to impact improvement in vascular stiffness.
New Drug Product: Viltepso
This slideshow shows drug information for Viltepso. Click here for the complete Viltepso monograph.
Casimersen Gets Priority Review for Duchenne Muscular Dystrophy
Casimersen is a phosphorodiamidate morpholino oligomer that works by binding to exon 45 of dystrophin pre-mRNA.
Upadacitinib Application for Ankylosing Spondylitis Submitted for Review
The application is supported by data from the multicenter, double-blind, placebo-controlled phase 2/3 SELECT-AXIS 1 study.
